3-N-Butylphthalide
The risk or severity of adverse effects can be increased when Butylphthalide is combined with Methyl salicylate.
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with Methyl salicylate.
Acarbose
Methyl salicylate may increase the hypoglycemic activities of Acarbose.
Advertisement
Acenocoumarol
Methyl salicylate may increase the anticoagulant activities of Acenocoumarol.
Acetazolamide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Acetazolamide.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methyl salicylate.
Advertisement
Albiglutide
Methyl salicylate may increase the hypoglycemic activities of Albiglutide.
Alclometasone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Alclometasone.
Aldosterone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Aldosterone.
Advertisement
Alogliptin
Methyl salicylate may increase the hypoglycemic activities of Alogliptin.
Aloxiprin
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Aloxiprin.
Alprostadil
The risk or severity of adverse effects can be increased when Alprostadil is combined with Methyl salicylate.
Alteplase
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Alteplase.
Amcinonide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Amcinonide.
Aminosalicylic Acid
Aminosalicylic Acid may increase the anticoagulant activities of Methyl salicylate.
Ammonium Chloride
The serum concentration of Methyl salicylate can be increased when it is combined with Ammonium chloride.
Anagrelide
The risk or severity of adverse effects can be increased when Anagrelide is combined with Methyl salicylate.
Ancrod
Methyl salicylate may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Androstenedione.
Anistreplase
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Anistreplase.
Antithrombin III
Methyl salicylate may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Methyl salicylate may increase the anticoagulant activities of Antithrombin III human.
Apixaban
Methyl salicylate may increase the anticoagulant activities of Apixaban.
Ardeparin
Methyl salicylate may increase the anticoagulant activities of Ardeparin.
Argatroban
The risk or severity of adverse effects can be increased when Argatroban is combined with Methyl salicylate.
Argatroban Anhydrous
The risk or severity of adverse effects can be increased when Argatroban is combined with Methyl salicylate.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methyl salicylate.
Astaxanthin
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Astaxanthin.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Methyl salicylate.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Methyl salicylate.
Balsalazide
Balsalazide may increase the anticoagulant activities of Methyl salicylate.
Becaplermin
Methyl salicylate may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Beclomethasone dipropionate.
Bemiparin
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Bemiparin.
Benazepril
The therapeutic efficacy of Benazepril can be decreased when used in combination with Methyl salicylate.
Betamethasone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Betamethasone.
Bivalirudin
Methyl salicylate may increase the anticoagulant activities of Bivalirudin.
Brinzolamide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Brinzolamide.
Bromocriptine
Methyl salicylate may increase the hypoglycemic activities of Bromocriptine.
Budesonide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Budesonide.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Methyl salicylate.
Canagliflozin
Methyl salicylate may increase the hypoglycemic activities of Canagliflozin.
Canagliflozin Anhydrous
Methyl salicylate may increase the hypoglycemic activities of Canagliflozin.
Cangrelor
The risk or severity of adverse effects can be increased when Cangrelor is combined with Methyl salicylate.
Captopril
The therapeutic efficacy of Captopril can be decreased when used in combination with Methyl salicylate.
Certoparin
Methyl salicylate may increase the anticoagulant activities of Certoparin.
Chlorpropamide
Methyl salicylate may increase the hypoglycemic activities of Chlorpropamide.
Ciclesonide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ciclesonide.
Cilazapril
The therapeutic efficacy of Cilazapril can be decreased when used in combination with Methyl salicylate.
Cilostazol
The risk or severity of adverse effects can be increased when Cilostazol is combined with Methyl salicylate.
Citric Acid
Methyl salicylate may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Methyl salicylate may increase the anticoagulant activities of Citric Acid.
Clobetasol
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clocortolone.
Clopidogrel
The risk or severity of adverse effects can be increased when Clopidogrel is combined with Methyl salicylate.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Cortisone acetate.
Dabigatran Etexilate
Methyl salicylate may increase the anticoagulant activities of Dabigatran etexilate.
Dalteparin
Methyl salicylate may increase the anticoagulant activities of Dalteparin.
Danaparoid
Methyl salicylate may increase the anticoagulant activities of Danaparoid.
Dapagliflozin
Methyl salicylate may increase the hypoglycemic activities of Dapagliflozin.
Defibrotide
The risk or severity of adverse effects can be increased when Defibrotide is combined with Methyl salicylate.
Deflazacort
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Deflazacort.
Desirudin
Methyl salicylate may increase the anticoagulant activities of Desirudin.
Desonide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desoxycorticosterone Pivalate.
Dexamethasone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dexketoprofen.
Dextran
Methyl salicylate may increase the anticoagulant activities of Dextran.
Dextran 40
Methyl salicylate may increase the anticoagulant activities of Dextran 40.
Dextran 70
Methyl salicylate may increase the anticoagulant activities of Dextran 70.
Dextran 75
Methyl salicylate may increase the anticoagulant activities of Dextran 75.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Diclofenamide.
Dicumarol
Methyl salicylate may increase the anticoagulant activities of Dicoumarol.
Diflorasone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Difluocortolone.
Diflunisal
Diflunisal may increase the anticoagulant activities of Methyl salicylate.
Difluprednate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Difluprednate.
Diltiazem
Diltiazem may increase the anticoagulant activities of Methyl salicylate.
Dipyridamole
The risk or severity of adverse effects can be increased when Dipyridamole is combined with Methyl salicylate.
Disopyramide
Methyl salicylate may increase the hypoglycemic activities of Disopyramide.
Dorzolamide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dorzolamide.
Drotrecogin Alfa
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Drotrecogin alfa.
Dulaglutide
Methyl salicylate may increase the hypoglycemic activities of Dulaglutide.
Edetic Acid
Methyl salicylate may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Methyl salicylate may increase the anticoagulant activities of Edoxaban.
Empagliflozin
Methyl salicylate may increase the hypoglycemic activities of Empagliflozin.
Enalapril
The therapeutic efficacy of Enalapril can be decreased when used in combination with Methyl salicylate.
Enalaprilat
The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Methyl salicylate.
Enalaprilat Anhydrous
The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Methyl salicylate.
Enoxaparin
Methyl salicylate may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Methyl salicylate may increase the anticoagulant activities of Enoxaparin.
Epinastine
The risk or severity of adverse effects can be increased when Epinastine is combined with Methyl salicylate.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Methyl salicylate.
Eptifibatide
The risk or severity of adverse effects can be increased when Eptifibatide is combined with Methyl salicylate.
Estrone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Estrone.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methyl salicylate.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methyl salicylate.
Ethylenediaminetetraacetate
Methyl salicylate may increase the anticoagulant activities of Edetic Acid.
Exenatide
Methyl salicylate may increase the hypoglycemic activities of Exenatide.
Ferulic Acid
Methyl salicylate may increase the anticoagulant activities of Ferulic acid.
Fludrocortisone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fludrocortisone.
Fluindione
Methyl salicylate may increase the anticoagulant activities of Fluindione.
Flumethasone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluorometholone.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Flurandrenolide.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluticasone propionate.
Fondaparinux
Methyl salicylate may increase the anticoagulant activities of Fondaparinux.
Fondaparinux sodium
Methyl salicylate may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Formestane.
Fosinopril
The therapeutic efficacy of Fosinopril can be decreased when used in combination with Methyl salicylate.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Methyl salicylate.
Ginkgo biloba extract
Ginkgo biloba may increase the anticoagulant activities of Methyl salicylate.
Gliclazide
Methyl salicylate may increase the hypoglycemic activities of Gliclazide.
Glimepiride
Methyl salicylate may increase the hypoglycemic activities of Glimepiride.
Glipizide
Methyl salicylate may increase the hypoglycemic activities of Glipizide.
Glyburide
Methyl salicylate may increase the hypoglycemic activities of Glyburide.
Halcinonide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ulobetasol.
Heparin
Methyl salicylate may increase the anticoagulant activities of Heparin.
Hyaluronidase
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methyl salicylate.
Hyaluronidase, Ovine
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methyl salicylate.
Hydrocortisone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone.
Hydroxytyrosol
The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Methyl salicylate.
Icosapent Ethyl
The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Methyl salicylate.
Ifenprodil
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Methyl salicylate.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Methyl salicylate.
Imidapril
The therapeutic efficacy of Imidapril can be decreased when used in combination with Methyl salicylate.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Methyl salicylate.
Insulin Detemir
Methyl salicylate may increase the hypoglycemic activities of Insulin Detemir.
Insulin Glargine
Methyl salicylate may increase the hypoglycemic activities of Insulin Glargine.
insulin human, rDNA origin
Methyl salicylate may increase the hypoglycemic activities of Insulin Human.
Insulin Lispro
Methyl salicylate may increase the hypoglycemic activities of Insulin Lispro.
Insulin, Aspart Protamine, Human
Methyl salicylate may increase the hypoglycemic activities of Insulin Aspart.
Insulin, Aspart, Human
Methyl salicylate may increase the hypoglycemic activities of Insulin Aspart.
Insulin, Glulisine, Human
Methyl salicylate may increase the hypoglycemic activities of Insulin Glulisine.
Insulin, Protamine Lispro, Human
Methyl salicylate may increase the hypoglycemic activities of Insulin Lispro.
Ketanserin
The risk or severity of adverse effects can be increased when Ketanserin is combined with Methyl salicylate.
Lepirudin
Methyl salicylate may increase the anticoagulant activities of Lepirudin.
Liraglutide
Methyl salicylate may increase the hypoglycemic activities of Liraglutide.
Lisinopril
The therapeutic efficacy of Lisinopril can be decreased when used in combination with Methyl salicylate.
Lisinopril Anhydrous
The therapeutic efficacy of Lisinopril can be decreased when used in combination with Methyl salicylate.
Loteprednol
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Loteprednol.
Mecasermin
Methyl salicylate may increase the hypoglycemic activities of Mecasermin.
Mecasermin Rinfabate
Methyl salicylate may increase the hypoglycemic activities of Mecasermin.
Medrysone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Medrysone.
Mesalamine
Mesalazine may increase the anticoagulant activities of Methyl salicylate.
Metformin
Methyl salicylate may increase the hypoglycemic activities of Metformin.
Methazolamide
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Methazolamide.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Methyl salicylate.
Methylprednisolone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Methylprednisolone.
Mifepristone
Methyl salicylate may increase the hypoglycemic activities of Mifepristone.
Miglitol
Methyl salicylate may increase the hypoglycemic activities of Miglitol.
Milrinone
The risk or severity of adverse effects can be increased when Milrinone is combined with Methyl salicylate.
Moexipril
The therapeutic efficacy of Moexipril can be decreased when used in combination with Methyl salicylate.
Mometasone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Mometasone.
Nadroparin
Methyl salicylate may increase the anticoagulant activities of Nadroparin.
Nateglinide
Methyl salicylate may increase the hypoglycemic activities of Nateglinide.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Methyl salicylate.
Olsalazine
Olsalazine may increase the anticoagulant activities of Methyl salicylate.
Paramethasone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Paramethasone.
Parnaparin
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Parnaparin.
Pentaerythritol Tetranitrate
Methyl salicylate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentamidine
Methyl salicylate may increase the hypoglycemic activities of Pentamidine.
Pentosan Polysulfate
Methyl salicylate may increase the anticoagulant activities of Pentosan Polysulfate.
Pentoxifylline
The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Methyl salicylate.
Perindopril
The therapeutic efficacy of Perindopril can be decreased when used in combination with Methyl salicylate.
Phenindione
Methyl salicylate may increase the anticoagulant activities of Phenindione.
Phenprocoumon
Methyl salicylate may increase the anticoagulant activities of Phenprocoumon.
Pioglitazone
Methyl salicylate may increase the hypoglycemic activities of Pioglitazone.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Methyl salicylate.
Plasmin
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fibrinolysin.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Methyl salicylate.
Pramlintide
Methyl salicylate may increase the hypoglycemic activities of Pramlintide.
Prasterone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prasterone.
Prasugrel
The risk or severity of adverse effects can be increased when Prasugrel is combined with Methyl salicylate.
Prednicarbate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Pregnenolone.
Probenecid
The therapeutic efficacy of Probenecid can be decreased when used in combination with Methyl salicylate.
protein C, human
Methyl salicylate may increase the anticoagulant activities of Protein C.
protein S, human
Methyl salicylate may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Methyl salicylate may increase the anticoagulant activities of Protocatechualdehyde.
Quinapril
The therapeutic efficacy of Quinapril can be decreased when used in combination with Methyl salicylate.
Quinine
Methyl salicylate may increase the hypoglycemic activities of Quinine.
Ramipril
The therapeutic efficacy of Ramipril can be decreased when used in combination with Methyl salicylate.
Regular Insulin, Human
Methyl salicylate may increase the hypoglycemic activities of Insulin Human.
Repaglinide
Methyl salicylate may increase the hypoglycemic activities of Repaglinide.
Rescinnamine
The therapeutic efficacy of Rescinnamine can be decreased when used in combination with Methyl salicylate.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Methyl salicylate.
Reteplase
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Reteplase.
Reviparin
Methyl salicylate may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Methyl salicylate may increase the anticoagulant activities of Reviparin.
Rimexolone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Rimexolone.
Rivaroxaban
Methyl salicylate may increase the anticoagulant activities of Rivaroxaban.
Rosiglitazone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Rosiglitazone.
Salicylic Acid
Salicylic acid may increase the anticoagulant activities of Methyl salicylate.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Methyl salicylate.
Saxagliptin
Methyl salicylate may increase the hypoglycemic activities of Saxagliptin.
Saxagliptin Anhydrous
Methyl salicylate may increase the hypoglycemic activities of Saxagliptin.
Selexipag
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Selexipag.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Methyl salicylate.
Sitagliptin
Methyl salicylate may increase the hypoglycemic activities of Sitagliptin.
Sitagliptin Phosphate
Methyl salicylate may increase the hypoglycemic activities of Sitagliptin.
Spirapril
The therapeutic efficacy of Spirapril can be decreased when used in combination with Methyl salicylate.
Streptokinase
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Streptokinase.
Sulfadiazine
Methyl salicylate may increase the hypoglycemic activities of Sulfadiazine.
Sulfamethoxazole
Methyl salicylate may increase the hypoglycemic activities of Sulfamethoxazole.
Sulfisoxazole
Methyl salicylate may increase the hypoglycemic activities of Sulfisoxazole.
Sunitinib
Methyl salicylate may increase the hypoglycemic activities of Sunitinib.
Tenecteplase
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Tenecteplase.
Ticagrelor
The risk or severity of adverse effects can be increased when Ticagrelor is combined with Methyl salicylate.
Ticlopidine
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ticlopidine.
Tinzaparin
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Tinzaparin.
Tinzaparin sodium
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Tinzaparin.
Tirofiban
The risk or severity of adverse effects can be increased when Tirofiban is combined with Methyl salicylate.
Tixocortol
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Tixocortol.
Tolazamide
Methyl salicylate may increase the hypoglycemic activities of Tolazamide.
Tolbutamide
Methyl salicylate may increase the hypoglycemic activities of Tolbutamide.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Methyl salicylate.
Trandolapril
The therapeutic efficacy of Trandolapril can be decreased when used in combination with Methyl salicylate.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Methyl salicylate.
Trapidil
The risk or severity of adverse effects can be increased when Trapidil is combined with Methyl salicylate.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Methyl salicylate.
Triamcinolone
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Triamcinolone.
Triflusal
The risk or severity of adverse effects can be increased when Triflusal is combined with Methyl salicylate.
Trolamine Salicylate
Methyl salicylate may increase the anticoagulant activities of Trolamine salicylate.
Troxerutin
Methyl salicylate may increase the anticoagulant activities of Troxerutin.
Urokinase
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Urokinase.
Valproate
The serum concentration of Valproic Acid can be increased when it is combined with Methyl salicylate.
Valproic Acid
The serum concentration of Valproic Acid can be increased when it is combined with Methyl salicylate.
Verapamil
Verapamil may increase the anticoagulant activities of Methyl salicylate.
Vorapaxar
The risk or severity of adverse effects can be increased when Vorapaxar is combined with Methyl salicylate.
Warfarin
Methyl salicylate may increase the anticoagulant activities of Warfarin.
Zofenopril
The therapeutic efficacy of Zofenopril can be decreased when used in combination with Methyl salicylate.
